Andreas L. Marzinzik

The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1

Andrew A. Wylie, Joseph Schoepfer, Wolfgang Jahnke et al. · Nature · 2017 · 596 citations

Pharmacy, Medicinal Chemistry, Pharmacology +15

Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1

Joseph Schoepfer, Wolfgang Jahnke, Giuliano Berellini et al. · Journal of Medicinal Chemistry · 2018 · 447 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

Safe and Reliable Synthesis of Diazoketones and Quinoxalines in a Continuous Flow Reactor

Laetitia J. Martin, Andreas L. Marzinzik, Steven V. Ley et al. · Organic Letters · 2010 · 133 citations · Full text

Natural Sciences, Chemical Engineering, Chemistry +17

Binding or Bending: Distinction of Allosteric Abl Kinase Agonists from Antagonists by an NMR-Based Conformational Assay

Wolfgang Jahnke, Robert M. Grotzfeld, Xavier Pellé et al. · Journal of the American Chemical Society · 2010 · 125 citations

Pharmacy, Medicinal Chemistry, Pharmacology +16

Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery

Wolfgang Jahnke, Jean‐Michel Rondeau, Simona Cotesta et al. · Nature Chemical Biology · 2010 · 125 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14